RNS60 aids mitochondria health, protects motor neurons in ALS mice

NeuroSense moving to request early approval of PrimeC in Canada

NeuroSense Therapeutics has initiated the process of applying to Canada’s regulators for early marketing approval of PrimeC in treating amyotrophic lateral sclerosis (ALS), based on positive findings in a Phase 2b clinical trial. The application will be filed under Health Canada’s Notice of Compliance with Conditions policy, which could…

Good memories sustain us when life with ALS is hard

I like the Maroon 5 song “Memories” because I’m soothed by the melody, borrowed from Johann Pachelbel’s Canon in D, and I’m moved by the lyrics. One line in particular resonates with me: “The memories bring back you.” Though my husband, Todd, is still with me,…

Highly targeted approach supports ALS gene therapy development

Researchers have developed a type of gene therapy that can rescue the function of the TDP-43 protein in diseased nerve cells in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases while leaving healthy cells untouched. The approach uses problematic sequences called cryptic exons that are only present in cells…

Neuvivo requests FDA approval of ALS treatment NP001

Neuvivo has filed an application with the U.S. Food and Drug Administration (FDA) requesting the approval of its investigational therapy NP001 (sodium chlorite) to treat amyotrophic lateral sclerosis (ALS). The new drug application comes on the heels of combined data from Phase 2a (NCT01281631) and Phase…

Immune proteins activation at ALS diagnosis linked to progression

Researchers detected changes in the production of several immune signaling proteins, called cytokines, in the cerebrospinal fluid (CSF) — the liquid that surrounds the brain and spinal cord — of people with amyotrophic lateral sclerosis (ALS) at diagnosis. These changes also correlated with certain clinical characteristics, and how quickly the…